Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.
Stage one results from PLL Therapeutics’ first-in-human, multi-stage phase I/II trial show favorable safety and tolerability of PLL001 in 12 ALS patients Australian multi-stage study tested single ...
Pharmaceutical Technology on MSN
J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC
The therapy dosing provides clinical outcomes consistent with those of the earlier approved bi-weekly subcutaneous regimen.
Indiana lawmakers are weighing new guardrails around drug compounding amid warnings that patients are receiving powerful prescription treatments in settings that operate largely outside state ...
The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.
The consensus narrative frames Merck as a one-product company facing an existential patent cliff in 2028. Wefundamentally disagree with this characterization. Merck is executing one of the most ...
Fourth Quarter 2025 Revenue Increase of 31% (29% Constant Currency1) andFull Year 2025 Revenue Increase of 31% Year-Over-Year (30% Constant Currency)Represents 10th Consecutive Year of 20% or More ...
News-Medical.Net on MSN
Injectable clay-based bandages rapidly stop severe internal bleeding
Traumatic injury is the third leading cause of death in the state of Texas, surpassing strokes, Alzheimer's disease and diabetes, according to the Centers for Disease Control and Prevention. A massive ...
Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results